| Literature DB >> 30060470 |
Didier Jean1,2,3,4, Marie-Claude Jaurand5,6,7,8.
Abstract
Malignant mesothelioma (MM), a rare and severe cancer, mainly caused as a result of past-asbestos exposure, is presently a public health concern. Current molecular studies aim to improve the outcome of the disease, providing efficient therapies based on the principles of precision medicine. To model the molecular profile of human malignant mesothelioma, animal models have been developed in rodents, wild type animals and genetically engineered mice harbouring mutations in tumour suppressor genes, especially selecting genes known to be inactivated in human malignant mesothelioma. Animals were either exposed or not exposed to asbestos or to other carcinogenic fibres, to understand the mechanism of action of fibres at the molecular level, and the role of the selected genes in mesothelial carcinogenesis. The aim of the manuscript was to compare mesothelioma models to human malignant mesothelioma and to specify the clue genes playing a role in mesothelial carcinogenesis. Collectively, MM models recapitulate the clinical features of human MM. At least two altered genes are needed to induce malignant mesothelioma in mice. Two pathways regulated by Cdkn2a and Trp53 seem independent key players in mesothelial carcinogenesis. Other genes and pathways appear as bona fide modulators of the neoplastic transformation.Entities:
Keywords: carcinogenesis; gene mutations; malignant mesothelioma; mesothelium; mineral fibres; signalling pathways; tumor suppressor genes
Mesh:
Year: 2018 PMID: 30060470 PMCID: PMC6121615 DOI: 10.3390/ijms19082191
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Induction of murine mesotheliomas (MuMM) in genetically engineered mice (GEM) (Injection of AdCre in GEM 1).
| Gene(s) Affected | Gene(s) Status | MuMM % | Epi 2 % | Sarco 2 % | Mixed % | Survival 3 Weeks | Reference |
|---|---|---|---|---|---|---|---|
|
| Htz | 34 4 | 28.6 | 21.4 | 50 | 58 5 | [ |
|
| Hom | 34.6 4 | 22.2 | 27.8 | 50 | 71 5 | [ |
|
| Hom | 79 4 | 2.2 | 68.9 | 28.9 | 31 5 | [ |
|
| Htz | 5.9 4 | 0 | Primarily sarco | Some mixed | ND 7 | [ |
|
| Hom | 13.3 4 | 0 | Primarily sarco | Some mixed | ND | [ |
|
| Hom | 26.3 4 | 0 | Primarily sarco | Some mixed | ND | [ |
|
| Htz | 6.75 6 | 0 | Primarily sarco | Some mixed | ND | [ |
|
| Hom | 13.3 6 | 0 | Primarily sarco | Some mixed | ND | [ |
|
| Hom | 20 6 | 0 | Primarily sarco | Some mixed | ND | [ |
|
| Htz | 59 4 | 25 | 25 | 50 | 29 5 | [ |
|
| Hom | 25 4 | 60 | 40 | 0 | 86 5 | [ |
|
| Hom | 82 4 | 15.5 | 46.7 | 37.8 | 19 5 | [ |
|
| Hom | 93.7 4 | 0 | 40 | 60 | ND | [ |
|
| Hom | 91.1 4 | 0 | 76.6 | 23.4 | 11 | [ |
|
| Hom | 85 6 | Mostly | 37 | [ | ||
|
| Hom | 0 6 | NA 7 | >57 | [ | ||
|
| WT | 0 6 | NA | >57 | [ | ||
|
| WT | 0 6 | NA | >57 | [ | ||
|
| Hom | 73 8 | Mostly | 44 | [ | ||
|
| Hom | 0 8 | NA | >57 | [ | ||
|
| WT | 0 8 | NA | >57 | [ | ||
|
| WT | 0 8 | NA | >57 | [ |
1 Strain of mice: FVB/N [59]; Hybrids [58]; 2 Epi.: Epithelioid; Sarco.: Sarcomatoid; 3 Median survival of the series; 4 After intrathoracic injection of AdCre; 5 Mice with thoracic tumours; 6 After intraperitoneal injection of AdCre; 7 ND: Not done; NA: Not applicable; 8 After injection of AdCre in the bladder.
Induction of MuMM in GEM (Induction of MuMM by injection of fibres).
| Mice Strain | Gene(s) Affected | Gene(s) Status | Treatment | MuMM % | Epi 2 % | Sarco 2 % | Mixed % | Survival 3 Weeks | Reference |
|---|---|---|---|---|---|---|---|---|---|
| FVB/N |
| Htz | Asbestos | 47 | 30.4 Htz + WT | 65.2 Htz + WT | 4.3 Htz + WT | [ | |
| FVB/N | None | WT | Asbestos | 15 | 30.4 Htz + WT | 65.2 Htz + WT | 4.3 Htz + WT | [ | |
| FVB/N |
| Htz | Saline | 0 | NA | NA | NA | [ | |
| FVB/N | None | WT | Saline | 0 | NA | NA | NA | [ | |
| 129Sv/Jae |
| Htz | Asbestos | 85 | 6.25 | 18.75 | 75 | 43 | [ |
| 129Sv/Jae | None | WT | Asbestos | 59 | 31 | 27.6 | 41.4 | 52 | [ |
| FVB/N |
| Htz | RCF | 55 | 27 | 38.4 | 34.6 | 68 | [ |
| FVB/N | None | WT | RCF | 7.1 | 0 | 0 | 100 | 80 | [ |
| C57/Bl6 |
| Htz | Asbestos | 10 | ND | ND | ND | ND | [ |
| C57/Bl6 |
| Htz | Asbestos | 96.2 | 68 | 12 | 20 | 42 | [ |
| C57/Bl6 | None | WT | Asbestos | 81.5 | 68.2 | 18.2 | 13.6 | 56 | [ |
| Hybrids |
| Htz | Asbestos | 88 | Occasional | Prevalent | Occasional | 29.6 | [ |
| Hybrids |
| Htz | TiO2 | 0 | NA | NA | NA | NA | [ |
| Hybrids |
| Htz | Asbestos | 66 | Occasional | Prevalent | Occasional | 34.6 | [ |
| Hybrids |
| Htz | Asbestos | 65 | Occasional | Prevalent | Occasional | 38 | [ |
| Hybrids | None | WT | Asbestos | 50 | Occasional | Prevalent | Occasional | 49.4 | [ |
| Hybrids |
| Htz | Asbestos | ND | ND | ND | ND | 38 | [ |
| Hybrids |
| HtzHtz | Asbestos | ND | ND | Most sarcomatous | ND | 24 | [ |
| Hybrids | None | WT | Asbestos | ND | ND | ND | ND | 45 | [ |
| 129/Sv on a 75% C57/Bl6 background |
| Htz | Asbestos | 76 (after 44 weeks) | ND | ND | ND | [ | |
| 129/Sv on a 75% C57/Bl6 background |
| Hom | Asbestos | ND | ND | ND | ND | [ | |
| 129/Sv on a 75% C57/Bl6 background | None | WT | Asbestos | 32 (after 67 weeks) | ND | ND | ND | [ | |
| FVB |
| Htz | Asbestos | 73 | ND | ND | ND | 43 | [ |
| FVB | None | WT | Asbestos | 32 | ND | ND | ND | 55 | [ |
| FVB |
| Htz (L) | Asbestos | 71 | ND | ND | ND | 46 | [ |
| FVB |
| Htz (W) | Asbestos | 74 | ND | ND | ND | 48 | [ |
| FVB | None | WT | Asbestos | 35 | ND | ND | ND | 60 | [ |
| C57BL/6 |
| Htz | Asbestos low dose | 36 | all or part | 57 | [ | ||
| C57BL/6 | None | WT | Asbestos low dose | 10 | all or part | 57 | [ | ||
| C57BL/6 | None | WT | Saline | 0 | NA | NA | [ | ||
| C57BL/6 |
| Htz | Asbestos std dose | 60 | all or part | 39 | [ | ||
| C57BL/6 |
| WT | Asbestos std dose | 28 | all or part | 57 | [ | ||
| C57BL/6 |
| Hom | Asbestos | 55 | 0 | 75 | 25 | 66.2 | [ |
| C57BL/6 |
| Htz | Asbestos | 65 | 0 | 68 | 32 | 69.4 | [ |
| C57BL/6 | None | WT | Asbestos | 80 | 0 | 67 | 33 | OK | [ |
2 Epi.: Epithelioid; Sarco.: Sarcomatoid; 3 Median survival of the series.